August 2026—Testing for homologous recombination deficiency (HRD) is not for the faint of heart. Even the experts agree. Tricia Numan, MD, says that when she first became involved in the topic, “I didn’t realize how many components went into HRD testing,” including germline alterations, somatic alterations, and various classifications of genomic instability.
August 2026—In a summer of more ticks, more diseases, and more tick species expanding to new areas and bringing diseases with them, what Bobbi Pritt, MD, MSc, would like to see are more—and better—diagnostics in early Lyme disease. Laboratory scientists are inching toward improved solutions, though nothing is commercially available now. “I’m cautiously optimistic. I wouldn’t say I’m excited yet,” says Dr. Pritt, co-director of vector-borne diseases laboratory services and chair of the Division of Clinical Microbiology at Mayo Clinic in Rochester.
July 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on July 21, 2026 with Nick Fingland, PhD, PMP, Senior Director R&D Operations and Science, BD, and Chris Farnsworth, PhD D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Watch the full conversation:
This roundtable discussion is sponsored by BD.
MAGNUS DECAL redefines tissue processing by integrating automated bone marrow decalcification directly into the processing workflow. Learn More
August 2026—At the upcoming CAP26 annual meeting in Las Vegas, you might notice key differences compared with our past meetings. We know some elements that were once compelling reasons to attend conferences, such as CME credits, are no longer the draw they used to be.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: chemistry/immunoassay analyzers for mid- and high-volume labs
July 2026—Roche’s new Cobas Mass Spec solution will be on display this month at the ADLM meeting, as will Diasorin’s new Liaison Nes, Siemens Healthineers’ Atellica DT 250, and much more. CAP TODAY publisher Bob McGonnagle spoke online in late May with representatives of Roche, Diasorin, Sebia, and Siemens Healthineers about how their instruments will solve some of laboratories’ pressing problems. The conversation follows.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
June 2021—T2 Biosystems announced that Expert Review of Medical Devices published meta-analysis findings confirming that using the company’s magnetic resonance (T2MR) technology for identification of bloodstream infections provides faster time to detection, faster transition to targeted microbial therapy, faster de-escalation of empirical therapy, and shorter intensive care unit and hospital stay, and with comparable mortality rate versus the current blood culture standard (Giannella M, et al. Online ahead of print April 16, 2021. doi:10.1080/17434440.2021.1919508). Study authors systematically searched Medline, Embase, and Cochrane Central Register of Controlled Trials for randomized trials or observational controlled studies of patients with suspected bloodstream infections receiving a diagnosis with T2MR or blood culture, ultimately including 14 studies.